The sodium iodide symporter: its pathophysiological and therapeutic implications.
about
Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cellsThe sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapiesMeasles to the Rescue: A Review of Oncolytic Measles VirusConserved charged amino acid residues in the extracellular region of sodium/iodide symporter are critical for iodide transport activity.Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus.Novel approaches in anaplastic thyroid cancer therapyTargeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoterEpidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene deliverySodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene deliveryStandard and emerging therapies for metastatic differentiated thyroid cancer.Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.Gene therapy progress and prospects: noninvasive imaging of gene therapy in living subjects.Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and backPhthalates Are Metabolised by Primary Thyroid Cell Cultures but Have Limited Influence on Selected Thyroid Cell Functions In VitroAssociation between sodium iodide symporter and differentiated Thyroid cancer: a meta-analysis of 9 studies.In Thyroidectomized Thyroid Cancer Patients, False-Positive I-131 Whole Body Scans Are Often Caused by Inflammation Rather Than Thyroid Cancer.Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer CellsStromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma.Analysis of the T354P mutation of the sodium/iodide cotransporter gene in children with congenital hypothyroidism due to dyshormonogenesis.TRPM7 is regulated by halides through its kinase domainThymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotectionAmerican Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models.The Na+/I- symporter (NIS): mechanism and medical impact.Genetics and phenomics of hypothyroidism and goiter due to NIS mutations.The mTOR protein as a target in thyroid cancer.Elevated thyroid stimulating hormone in a neonate: Drug induced or disease?Low iodine diet in differentiated thyroid cancer: a review.Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene.Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.Harnessing mesenchymal stem cell homing as an anticancer therapy.Effects of dietary supplementation of selenium and iodine on growth performance, carcass characteristics and histology of thyroid gland in goats.Synthesis and evaluation of 3,4-dihydropyrimidin-2(1H)-ones as sodium iodide symporter inhibitors.Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.Iodide sensitizes genetically modified non-small cell lung cancer cells to ionizing radiation.EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS GeneEstablishment of an Effective Radioiodide Thyroid Ablation Protocol in Mice.The G395R Mutation of the Sodium/Iodide Symporter (NIS) Gene in Patients with Dyshormonogenetic Congenital HypothyroidismSystemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes.
P2860
Q24793862-8FD779B1-5D5B-4A21-B6D0-5D66A4B0D847Q27023157-87B77E05-AB49-4664-B40A-281C52AB02D9Q28072097-FBAA04B5-5FF9-432E-9B73-75B4B73A270AQ30396481-49B2787A-A2E5-4D17-96E2-23B6342AF06CQ34168357-B7DA07C0-DDDF-4AFC-9A0F-62CD6470425DQ34303955-B773A0B9-E5DE-4B7D-9D92-5A1F35642D4DQ34458018-F20EE61D-A5B5-4782-B3FF-470135406396Q34512455-94E74868-6220-4DE7-9415-0E0AC193765BQ34757186-31526CD2-64D1-4CA1-AFFC-5EAA7A6745F2Q35238289-56978DAD-6182-40EE-8B83-8BC7D6088D71Q35575677-E3E6218B-153F-4E37-9946-A0D8C56683B1Q35583906-A15368DE-DB4C-4472-AF8D-7C7A6F988130Q35612571-CFD538A3-F7BA-4478-B643-316EA89931AFQ35623922-2F61D9B2-B405-4341-B931-5C696E50688DQ35915781-7ED96900-203B-410C-ACE7-0AF0C45EF6F8Q35960582-33E3EA5C-5FFD-492C-9CA0-22875928FFB4Q36411684-30E04717-19CC-4BF8-853E-2FC6A2BD4F82Q36645660-E94742A3-F175-4F79-A4E3-6AF39832FA3BQ36715993-36719476-2C51-413B-8D22-B5845AF6BB34Q36720696-0393B391-6651-4D76-8D67-2DE90558B9FCQ36861340-39478759-BDCC-4339-B510-C5BA8FC7FC86Q37008898-26DEDB2B-F86E-456E-8401-C102C0352207Q37168629-61BE2638-9136-497B-9B8C-733A17355410Q37460346-D3E5B250-87D9-49A6-B57D-877B7577A519Q37494004-B58B5413-3677-4799-A9BE-9A495130F3B7Q37691930-B9DE23C2-F76B-400D-964B-A276D2D06A82Q37894106-ABC9A98D-FF0E-453E-89EC-E40FCA071993Q38363453-9C46FAC9-4C9A-4331-B820-68E7E5E25F83Q38539352-1CB4113E-909A-4366-AFD4-7BD36AFFCB0CQ38772380-8A1F4ABF-DEA7-4028-971D-1A997C97D06EQ38823954-4679F821-1AA8-497E-B849-7C676E479343Q38857484-1563B98C-EDA4-41A9-8DC1-F5CD1F221B48Q38862306-ACDFBF52-F187-4C80-BDB2-874A289CC085Q39248523-C6CFEAA9-08E5-4227-BF8A-9FC99053319DQ40054917-C3EDA815-9858-4A99-92D8-7586BE6A1011Q40391796-B1E8F12D-9255-410F-8C43-2FF16CB8F49BQ41866984-7E648459-9604-45DA-9AB2-153D0606D596Q42127600-BE697D82-7C3A-4DCA-9C5A-3E443BCEC127Q42224903-CA9A3D25-09EE-4BA3-BEAA-578B330D7060Q45866837-1142BAD9-068F-4841-A49B-9F0D45252AAE
P2860
The sodium iodide symporter: its pathophysiological and therapeutic implications.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The sodium iodide symporter: its pathophysiological and therapeutic implications.
@ast
The sodium iodide symporter: its pathophysiological and therapeutic implications.
@en
The sodium iodide symporter: its pathophysiological and therapeutic implications.
@nl
type
label
The sodium iodide symporter: its pathophysiological and therapeutic implications.
@ast
The sodium iodide symporter: its pathophysiological and therapeutic implications.
@en
The sodium iodide symporter: its pathophysiological and therapeutic implications.
@nl
prefLabel
The sodium iodide symporter: its pathophysiological and therapeutic implications.
@ast
The sodium iodide symporter: its pathophysiological and therapeutic implications.
@en
The sodium iodide symporter: its pathophysiological and therapeutic implications.
@nl
P2860
P1476
The sodium iodide symporter: its pathophysiological and therapeutic implications.
@en
P2093
Christine Spitzweg
John C Morris
P2860
P304
P356
10.1046/J.1365-2265.2002.01640.X
P577
2002-11-01T00:00:00Z